Expert consensus on diagnosis and treatment of COVID-19 infection related cough in children.
10.3760/cma.j.cn112150-20230120-00052
- Collective Name:Child Allergy Professional Committee, China Association for Promotion of Health Science and Technology;Guangdong Zhongnanshan Medical Foundation;Children's Hospital Affiliated to Capital Institute of Pediatrics Union;Otolaryngology Group, Society of Pediatrics, Chinese Medical Doctor Association
- Publication Type:Journal Article
- MeSH:
Child;
Humans;
Cough/therapy*;
COVID-19/therapy*;
SARS-CoV-2;
Consensus;
COVID-19 Testing
- From:
Chinese Journal of Preventive Medicine
2023;57(3):309-317
- CountryChina
- Language:Chinese
-
Abstract:
An epidemic outbreak of the corona virus disease 2019(COVID-19) Omicron variant occurred in most regions of China. Children are susceptible to COVID-19 and the vast majority of them suffer from upper respiratory tract infection. Cough is one of the most common symptoms. COVID-19 infection related cough includes acute cough, persistent cough and chronic cough, and children with original chronic cough or chronic lung disease can also induce or aggravate symptom of cough after infection, which has a great impact on children's physical and mental health. The treatment for COVID-19 infection related cough vary with the etiology. Improper treatment would delay the patient's condition and increase adverse drug reaction. Currently, there is no guideline or consensus on the diagnosis and treatment of COVID-19 infection related cough in children in China, therefore this consensus is drafted. Referring to the latest international research and the diagnostic and therapeutic strategy for COVID-19 infection (Tenth Edition For Trial Implementation), and combining with clinical diagnosis and treatment experience,the consensus elaborates the pathogenesis and etiology of COVID-19 infection related cough, the use of cough relievers and expectorants, as well as the key points of diagnosis and treatment of different etiological factors. It is expected to provide specific and feasible guidance scheme for pediatricians, general practitioners and clinical pharmacists.
